v3.26.1
Description of Business (Details)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
May 05, 2025
USD ($)
tranche
Mar. 08, 2023
USD ($)
May 31, 2026
product
Jun. 30, 2026
USD ($)
Mar. 31, 2026
USD ($)
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Jun. 30, 2026
USD ($)
product
shares
Jun. 30, 2025
USD ($)
Mar. 03, 2026
USD ($)
Dec. 31, 2025
USD ($)
Subsidiary, Sale of Stock [Line Items]                      
Operating net loss       $ 4,543   $ 10,210   $ 11,391 $ 25,382    
Net loss       8,052 $ 10,674 $ 17,142 $ 18,892 18,726 36,034    
Net cash used in operating activities               13,539 $ 40,423    
Cash and cash equivalents       45,170       45,170     $ 53,826
Accumulated deficit       $ 679,766       $ 679,766     $ 661,040
ATM Sales Agreement                      
Subsidiary, Sale of Stock [Line Items]                      
Maximum consideration receivable   $ 50,000                  
Number of shares issued in transaction | shares               0      
New Pharmakon Term Loans | Line of Credit | Secured Debt                      
Subsidiary, Sale of Stock [Line Items]                      
Maximum borrowing capacity $ 250,000                    
Number of tranches | tranche 3                    
New Pharmakon Term Loans | Line of Credit | Revolving Credit Facility                      
Subsidiary, Sale of Stock [Line Items]                      
Maximum borrowing capacity, option $ 40,000                    
A&R Loan Agreement, Tranche One | Line of Credit | Secured Debt                      
Subsidiary, Sale of Stock [Line Items]                      
Debt drawn 150,000                    
A&R Loan Agreement, Tranche Two | Line of Credit | Secured Debt                      
Subsidiary, Sale of Stock [Line Items]                      
Maximum borrowing capacity 50,000                    
A&R Loan Agreement, Tranche Three | Line of Credit | Secured Debt                      
Subsidiary, Sale of Stock [Line Items]                      
Maximum borrowing capacity $ 50,000                    
Revolving Credit Facility | Line of Credit | Revolving Credit Facility                      
Subsidiary, Sale of Stock [Line Items]                      
Maximum borrowing capacity                   $ 30,000  
Line of credit facility, accordion feature, maximum limit                   10,000  
Uncommitted accordion feature, electable increment amount                   5,000  
Minimum utilization threshold, amount                   $ 10,000  
Symatese U.S. Agreement                      
Subsidiary, Sale of Stock [Line Items]                      
Expected regulatory approval, number of products | product               2      
Symatese Europe Agreement                      
Subsidiary, Sale of Stock [Line Items]                      
Number of products launched | product     4